EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement

Sampriti Paul iD, Sonal Dubey iD, Prashant Tiwari iD

Chemical Biology & Drug Design · 2026-07 · 108 (1)

DOI: 10.1111/cbdd.70366 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 23.07.2026. Verfasst von Sampriti Paul und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru South, India. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Protein Kinase Inhibitors. Die Arbeit nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual‐specificity tyrosine‐phosphorylation‐regulated kinase 1A (DYRK1A), located within the Down syndrome critical region and implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and context‐dependent cancer biology, represents a high‐value yet challenging therapeutic target. This review compiles comprehensive structure–activity relationship (SAR) insights essential for medicinal chemists designing selective DYRK1A inhibitors. We detail the molecular architecture of the ATP‐binding pocket of DYRK1A, key regulatory residues (Lys188, Phe238, Glu239, Leu241), and structure–function relationships governing inhibitor classes: ATP‐competitive agents, ATP‐non‐competitive inhibitors, and Proteolysis‐Targeting Chimeras (PROTAC) degraders with emphasis on functional group modifications and scaffold optimization strategies. Readers will gain actionable insights on binding mode predictions, potency‐selectivity trade‐offs, and prioritization of lead compounds for preclinical validation. The framework addresses pharmacokinetic property optimization and selectivity profiling across kinase families, enabling researchers to accelerate rational inhibitor design and facilitate translation of DYRK1A therapeutics into clinical trials for neurodegenerative and developmental disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesProtein Kinase InhibitorsDyrk KinasesProtein-Tyrosine KinasesHumansStructure-Activity RelationshipBinding SitesDrug DesignAdenosine TriphosphateProteolysis Targeting ChimeraTyrosine Kinase InhibitorsAnimals

Stichwörter der Autor:innen

Alzheimer diseaseDYRK1ADown syndromeprotein kinase inhibitorstructure–activity relationship

Substanzen

Dyrk KinasesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProtein Kinase InhibitorsAdenosine TriphosphateProteolysis Targeting ChimeraTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru South, India.

ORCID-Profile: Sampriti Paul, Sonal Dubey, Prashant Tiwari

Zitieren

APA

Paul, S., Dubey, S., & Tiwari, P. (2026). Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement. Chemical Biology & Drug Design, 108(1). https://doi.org/10.1111/cbdd.70366

Vancouver

Paul S, Dubey S, Tiwari P. Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement. Chemical Biology & Drug Design. 2026;108(1). doi:10.1111/cbdd.70366

BibTeX
@article{Paul2026,
  author = {Paul, Sampriti and Dubey, Sonal and Tiwari, Prashant},
  title = {Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {108},
  number = {1},
  doi = {10.1111/cbdd.70366}
}
Kostenlos starten →